-
06
2026
2026.06.10 -
Caliway Unveils Latest OI25 Animal Study Data for CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies at ADA 2026, Demonstrating Dual Potential to Attenuate Post-Discontinuation Weight Regain and Improve Metabolic Health
Caliway presented new OI25 preclinical data at ADA 2026 demonstrating that CBL-514, in combination with GLP-1R-based weight-loss therapies, enhanced weight-loss durability, attenuated post-discontinuation weight regain, and improved metabolic outcomes.
-
06
2026
2026.06.08 -
Caliway Announces IND Submission to U.S. FDA for CBL-514 Long-Term Follow-Up Phase 3 Trial (CBL-0303)
Seamlessly Extension Twin Pivotal Phase 3 Studies to Support NDA Pathway and Target the Global Broad-Area Non-Surgical Local Fat Reduction Market
-
05
2026
2026.05.22 -
Caliway Announces U.S. FDA IND Clearance for CBL-0302, Its Second Global Pivotal Phase 3 Study of CBL-514; Asia-Pacific Phase 2 Study CBL-0206 Also Approved by AU HREC and Taiwan TFDA, Accelerating Global Dual-Track Strategy
The Investigational New Drug (IND) application for CBL-0302 (SUPREME-02), Caliway’s second multi-country pivotal Phase 3 study for its localized fat reduction candidate CBL-514, has successfully passed the FDA's 30-day review period.
-
05
2026
2026.05.18 -
Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global Pharmaceutical Companies for Its Systemic Metabolic Effe
CBL-514, when combined separately with two leading GLP-1R-based weight-loss therapies, semaglutide and tirzepatide, demonstrated enhanced weight loss, attenuated post-discontinuation weight regain, and greater reductions in subcutaneous and visceral fat in animal studies. The presentation also marked the first disclosure at an international congress of CBL-514’s potential to improve liver metabolic indicators.
-
04
2026
2026.04.24 -
Caliway’s Asia-Pacific Phase 2 Study CBL-0206 Approved by Australia’s HREC to Proceed, Officially Advancing Asia-Pacific Clinical Strategy
Caliway’s Asia-Pacific Phase 2 study of CBL-514 for reduction of abdominal subcutaneous fat, CBL-0206, has received approval from Australia’s HREC to proceed, officially advancing the Company’s Asia-Pacific clinical strategy.
-
04
2026
2026.04.20 -
Caliway Completes U.S. FDA IND Submission for SUPREME-02, the Second Global Pivotal Phase 3 Study of CBL-514. Advancing Dual-Track Global Phase 3 Clinical Development
Caliway has completed the U.S. FDA IND submission for SUPREME-02, the second global multi-national, multi-center pivotal Phase 3 study of CBL-514 for reduction of abdominal subcutaneous fat, progressing on schedule according to the Company’s development plan.
-
04
2026
2026.04.09 -
Caliway's Fat Reduction Drug CBL-514 Phase 2 Clinical Results Accepted by ASJ. CBL-0204's Demonstrated Efficacy and Safety Gain Further Academic Recognition
Clinical results from CBL-0204 Phase 2b, a study of its first-in-class large-area localized fat reduction drug candidate, CBL-514, for subcutaneous fat reduction, have been accepted by the Aesthetic Surgery Journal (ASJ), a globally recognized authority in aesthetic medicine.
-
03
2026
2026.03.31 -
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association’s 2026 Scientific Sessions
Preclinical research on Caliway’s fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association’s 2026 Scientific Sessions.The presentation will be delivered by W. Timothy Garvey, MD, a globally recognized authority in obesity and metabolic medicine and a scientific advisor to Caliway.
